Analysts Set Expectations for TSE:BHC FY2024 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research increased their FY2024 earnings estimates for Bausch Health Companies in a research report issued to clients and investors on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will earn $4.98 per share for the year, up from their previous forecast of $4.88. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.50 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.56 EPS, Q4 2025 earnings at $1.73 EPS, FY2025 earnings at $5.77 EPS, Q1 2026 earnings at $1.50 EPS and Q2 2026 earnings at $1.50 EPS.

Several other research analysts have also recently weighed in on BHC. Raymond James raised Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 10th. Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th.

Bausch Health Companies Stock Performance

BHC opened at C$11.17 on Thursday. Bausch Health Companies has a 1-year low of C$5.45 and a 1-year high of C$15.43. The company has a market capitalization of C$4.10 billion, a price-to-earnings ratio of -6.38, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. The business has a 50 day moving average price of C$9.58 and a two-hundred day moving average price of C$9.93. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.19 and a quick ratio of 0.58.

Bausch Health Companies (TSE:BHC) last released its quarterly earnings results on Thursday, August 1st. The company reported C$1.22 EPS for the quarter, hitting analysts’ consensus estimates of C$1.22. The company had revenue of C$3.29 billion for the quarter, compared to the consensus estimate of C$3.20 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%.

Insider Buying and Selling at Bausch Health Companies

In other news, Senior Officer Seana Lynne Carson sold 13,370 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. 11.28% of the stock is owned by corporate insiders.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.